

## Type 2 diabetes in adults: management Guideline update - committee meeting

**Date:** Thursday 1<sup>st</sup> October 2020

**Location:** Virtual committee meeting by Zoom

**Minutes:** Final

<b>Committee members present:</b>	
Ibrahim Abubakar (IA)	Present for notes 1 – 6
Sarah Ali	Present for notes 2 – 6
Chirag Bakhai	Present for notes 1 – 6
Neel Basudev	Present for notes 1 – 6
Anne Dornhorst	Present for notes 1 – 6
Dorothy Frizelle	Present for notes 2 – 6
Hugh Gallagher	Present for notes 1 – 6
Natasha Jacques	Present for notes 1 – 6
Sallianne Kavanagh	Present for notes 1 – 6
Nicola Milne	Present for notes 1 – 6
Soon Song	Present for notes 1 – 6
Annette Swinkels	Present for notes 1 – 6
Gosia Wamil	Present for notes 1 – 6
Corrine Wykes	Present for notes 1 – 6

<b>NICE team in attendance:</b>		
Omnia Abdulrazeg	Technical Analyst	Present for notes 1 – 6
Rebecca Boucher	Senior Digital Editor	Present for notes 1 – 6
Lucy Beggs	Technical Adviser (Health Economics)	Present for notes 1 – 6
Jacqueline Durkin	Administrator	Present for notes 1 – 6
Rupert Franklin	Guideline Commissioning Manager	Present for notes 1 – 6
Sarah Glover	Information Specialist	Present for notes 1 – 6
Thomas Jones	Technical Analyst (Health Economics)	Present for notes 1 – 6
Marie Harrisingh	Senior Technical Analyst	Present for notes 1 – 6
Rebecca Parsons	Programme Manager	Present for notes 1 – 6
Gabriel Rogers	Technical Adviser (Health Economics)	Present for notes 1 – 6
Susan Spiers	Associate Director	Present for notes 1 – 6

<b>Apologies:</b>	
Augustin Brooks	Consultant Diabetologist
Sharon McCarthy	Diabetes Nurse

<b>NICE observers in attendance:</b>	
Emma Chambers	Public Involvement Adviser

### **1. Welcome and declarations of interest**

The Chair welcomed the Committee members and attendees to the 1st meeting on Type 2 diabetes in adults (pharma). The Chair informed the Committee that apologies from Augustin Brooks and Sharon McCarthy had been received. These are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: Management of type 2 diabetes in adults (pharma).

Committee members were then asked to provide a verbal summary of their declarations of interest. These are recorded on the declarations of interest register and will be published on the NICE website according to the NICE policy on declaring

interests.

The DOIs were considered by the Chair, no conflict of interest was identified for the meeting, and all Committee members were eligible to attend the Committee meeting and contribute to the discussions.

## **2. Introductions**

The Chair invited the committee members and NICE staff to introduce themselves and provide some information about their role and interest on the committee.

## **3. Committee discussion led by the technical team**

The Chair introduced the technical analyst, Omnia, who took the committee through the aims of the meeting and the scope of the update. Then she led a discussion about the decision points in the diabetes type 2 pharmacological treatment pathway and whether the assumptions from the previous version of the guideline were still valid.

## **4. Committee discussion led by the technical team continued**

The discussion about assumptions continued and finally moved onto possible review questions to address the clinical questions from the scope.

## **5. AOB**

Attendees of the meeting were invited to raise anything further for discussion under any other business. No further items were discussed.

## **6. Summary and next steps**

The Chair thanked the Committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

**Date of next meeting:** Friday 23<sup>rd</sup> October 2020

**Location of next meeting:** Virtual committee meeting by Zoom